RNAZ executed a third reverse stock split in 18 months while dramatically increasing assets through apparent financing, but losses more than doubled despite the capital infusion.
Three reverse splits in such a short timeframe (January 2024, December 2024, and May 2025 at 1:28 ratio) signals severe share price deterioration and potential delisting pressure. The massive asset increase suggests successful but likely dilutive equity financing, yet the company's burn rate accelerated significantly despite the capital raise.
The company's balance sheet was dramatically strengthened with total assets surging 2,126% to $162.4M and stockholders' equity turning positive at $10.3M, indicating a major capital raise or strategic transaction. However, operational performance deteriorated significantly with net losses more than doubling to -$34.7M and operating cash outflows increasing 46% to -$19.5M. The combination of massive asset growth alongside accelerating losses suggests the company raised substantial capital but is burning through it at an increasing rate, creating a concerning disconnect between balance sheet strength and operational deterioration.
Asset base grew 2126.3% — expansion through organic growth, acquisitions, or capital deployment.
Equity base grew 612% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 209.9% — improving short-term liquidity or inventory/receivables build.
Cash position surged 206.5% — strong cash generation or capital raise providing significant financial cushion.
Net income declined 106.9% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Capex reduced 69.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating cash flow fell 46.3% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 38.3% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →